Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Forero-Torres, A.; Wang, M.; Albertson, T. M.; Allen, T.; Sutherland, C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • WhiMSICAL (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering patients internationally to contribute patient-derived data for observational research
    Meeting Abstract

    Tohidi-Esfahani, I.; Warden, A.; deNardis, P.; Malunis, E.; D'Sa, S.; Kersten, M. J.; Palomba, M. L.; Spearing, R.; Ysebaert, L.; Thomas, S. K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom's Macroglobulinemia: Update of pivotal clinical trial
    Meeting Abstract

    Treon, S. P.; Meid, K.; Gustine, J.; Bantilan, K. S.; Dubeau, T.; Severns, P.; Yang, G.; Xu, L.; Patterson, C.; Ghobrial, I. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product, JCAR017
    Meeting Abstract

    Siddiqi, T.; Abramson, J. S.; Li, D.; Brown, W.; Devries, T.; Dave, K.; Garcia, J.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Preliminary safety profile of the CD19-directed defined composition CAR T cell product JCAR017 in relapsed/refractory aggressive B-NHL patients: Potential for outpatient administration
    Meeting Abstract

    Maloney, D. G.; Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero, A.; Albertson, T.; Garcia, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Active surveillance for newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
    Meeting Abstract

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C.; Caron, P.; Drullinsky, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): Defined composition allows for dose-finding and definition of pivotal cohort
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero, A.; Maloney, D. G.; Albertson, T.; Garcia, J.; more...
    Blood (2017)

    Fulltext@MSK | Save